Insiders · IRD

Robert E. Gagnon

Chief Financial Officer at Opus Genetics, Inc. (IRD) since September 2025

Robert E. Gagnon has filed 47 insider reports with the SEC since December 2021, as director at Bone Biologics Corp (BBLG), chief Financial Officer at Opus Genetics, Inc. (IRD) and director at Verastem, Inc. (VSTM) and at 3 more companies. In the last 12 months Robert E. Gagnon sold $193K of stock on the open market. The latest filing, on September 30, 2026, reports grant or award at Bone Biologics Corp (BBLG).

Filings
47
Companies
6
Bought on market
None
Sold on market
$527K

Companies where Robert E. Gagnon is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Bone Biologics Corp logo
BBLG
Bone Biologics Corp
Directorsince January 20240$0.2685Sep 30, 2026
Opus Genetics, Inc. logo
IRD
Opus Genetics, Inc.
Chief Financial Officersince September 2025556,375$191K$3.99Sep 8, 2026
Verastem, Inc. logo
VSTM
Verastem, Inc.
Directorsince December 202241,678$336K$6.33Jul 23, 2026
Harvard Bioscience Inc logo
HBIO
Harvard Bioscience Inc
Directorsince July 202527,556$8.66Jun 11, 2026
Purple Biotech Ltd. logo
PPBT
Purple Biotech Ltd.
Directorsince March 20263,062,500$1.525Mar 18, 2026
ESSA Pharma Inc. logo
EPIX
ESSA Pharma Inc.
DirectorJan 12, 2024

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Robert E. Gagnon with

Other insiders at the same companies

Questions about Robert E. Gagnon

What is Robert E. Gagnon's role at Opus Genetics, Inc.?
Robert E. Gagnon reports to the SEC as chief Financial Officer at Opus Genetics, Inc. (IRD), according to the latest filing on September 8, 2026. Robert E. Gagnon has also filed as director at Bone Biologics Corp (BBLG), director at Verastem, Inc. (VSTM), director at Harvard Bioscience Inc (HBIO) and director at Purple Biotech Ltd. (PPBT).
How many shares does Robert E. Gagnon own?
After the latest filing that states it, Robert E. Gagnon directly owned 556,375 shares of Opus Genetics, Inc. (IRD), 41,678 shares of Verastem, Inc. (VSTM), 27,556 shares of Harvard Bioscience Inc (HBIO) and 3,062,500 shares of Purple Biotech Ltd. (PPBT). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Robert E. Gagnon bought or sold stock recently?
The most recent open-market sale was on September 3, 2026: sold 28,000 shares of Opus Genetics, Inc. (IRD) for $127K at an average of $4.54.
How do I get alerts when Robert E. Gagnon files?
Follow Robert E. Gagnon on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale. Robert E. Gagnon filed 2 times in the last 90 days.

From SEC Forms 3, 4, 5 and 144 filed by Robert E. Gagnon (SEC CIK 0001504983). Totals count each trade once, skipping amendments whose original is on file, from Dec 17, 2021 on. View on SEC EDGAR · Get this as JSON